AR046094A1 - Anticuerpos completamente humanos contra 4-1bb humano - Google Patents
Anticuerpos completamente humanos contra 4-1bb humanoInfo
- Publication number
- AR046094A1 AR046094A1 ARP040103643A ARP040103643A AR046094A1 AR 046094 A1 AR046094 A1 AR 046094A1 AR P040103643 A ARP040103643 A AR P040103643A AR P040103643 A ARP040103643 A AR P040103643A AR 046094 A1 AR046094 A1 AR 046094A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- chain variable
- variable region
- antibody
- region comprises
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpos completamente humanos y porciones de enlace de antígenos de los mismos que se enlazan al 4-1BB humano y que permiten el enlace del 4-1BB humano al ligando 4-1BB humano, así como polinucleótidos que codifican dichos polipéptidos. En un aspecto el anticuerpo es el anticuerpo IgG4. También se suministra un método para el tratamiento del cáncer en un sujeto que comprende administrar una cantidad terapéuticamente efectiva del anticuerpo al sujeto. Reivindicación 1: Un anticuerpo monoclonal o porción de enlace de antígeno del mismo que se enlaza específicamente a 4-1BB, caracterizado porque comprende una región variable de cadena ligera una región variable de cadena pesada, en donde: la región variable de cadena ligera comprende un CDR1, un CDR2 y un CDR3 como se detalla en la figura (4); y la región variable de cadena pesada comprende un CDR1, un CDR2, y un CDR3 como se detalla en la figura (3).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51019303P | 2003-10-10 | 2003-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046094A1 true AR046094A1 (es) | 2005-11-23 |
Family
ID=37426115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103643A AR046094A1 (es) | 2003-10-10 | 2004-10-07 | Anticuerpos completamente humanos contra 4-1bb humano |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN1867585B (es) |
| AR (1) | AR046094A1 (es) |
| PE (1) | PE20050962A1 (es) |
| TW (1) | TWI332844B (es) |
| ZA (1) | ZA200602834B (es) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110357961A (zh) * | 2018-04-10 | 2019-10-22 | 无锡智康弘义生物科技有限公司 | 抗人4-1bb单克隆抗体及其制备方法和用途 |
| CN112010974A (zh) * | 2019-05-30 | 2020-12-01 | 山东博安生物技术有限公司 | 一种特异性结合人4-1bb的抗体及其应用 |
| US11555077B2 (en) | 2017-11-09 | 2023-01-17 | Shanghai Hyamab Biotech Co., Ltd. | 4-1BB antibody and preparation method and use thereof |
| US12054554B2 (en) | 2018-04-10 | 2024-08-06 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2810359C (en) * | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| RU2017142008A (ru) * | 2015-05-21 | 2019-06-24 | Эллигейтор Биосайенс Аб | Новые полипептиды |
| EP3354661B1 (en) | 2015-09-22 | 2020-06-03 | Dingfu Biotarget Co., Ltd. | Fully human antibody against human cd137 and use thereof |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| CA3039772C (en) | 2017-01-06 | 2020-08-25 | Eutilex Co., Ltd. | Anti-human 4-1bb antibodies and uses thereof |
| US11987635B2 (en) * | 2017-06-25 | 2024-05-21 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Anti-4-1BB antibodies and methods of making and using thereof |
| JP7402521B2 (ja) * | 2017-07-11 | 2023-12-21 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用 |
| CN111511762B (zh) * | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| RU2020127196A (ru) * | 2018-01-22 | 2022-02-24 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CN112867733B (zh) * | 2018-10-19 | 2023-01-06 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
| CN111320691B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人4-1bb单克隆抗体及其应用 |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029348A1 (en) * | 1995-03-23 | 1996-09-26 | Indiana University Foundation | Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases |
| JP2001502325A (ja) * | 1996-10-11 | 2001-02-20 | ブリストル―マイヤーズ・スクイブ・カンパニー | 免疫調整の方法および組成物 |
-
2004
- 2004-10-07 AR ARP040103643A patent/AR046094A1/es active IP Right Grant
- 2004-10-08 TW TW093130653A patent/TWI332844B/zh not_active IP Right Cessation
- 2004-10-11 PE PE2004000974A patent/PE20050962A1/es active IP Right Grant
- 2004-10-12 CN CN2004800297756A patent/CN1867585B/zh not_active Expired - Fee Related
-
2006
- 2006-04-06 ZA ZA200602834A patent/ZA200602834B/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11555077B2 (en) | 2017-11-09 | 2023-01-17 | Shanghai Hyamab Biotech Co., Ltd. | 4-1BB antibody and preparation method and use thereof |
| CN110357961A (zh) * | 2018-04-10 | 2019-10-22 | 无锡智康弘义生物科技有限公司 | 抗人4-1bb单克隆抗体及其制备方法和用途 |
| CN110357961B (zh) * | 2018-04-10 | 2022-08-23 | 无锡智康弘义生物科技有限公司 | 抗人4-1bb单克隆抗体及其制备方法和用途 |
| US12054554B2 (en) | 2018-04-10 | 2024-08-06 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof |
| CN112010974A (zh) * | 2019-05-30 | 2020-12-01 | 山东博安生物技术有限公司 | 一种特异性结合人4-1bb的抗体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200602834B (en) | 2007-07-25 |
| TWI332844B (en) | 2010-11-11 |
| PE20050962A1 (es) | 2005-11-17 |
| CN1867585A (zh) | 2006-11-22 |
| CN1867585B (zh) | 2011-02-09 |
| TW200517124A (en) | 2005-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046094A1 (es) | Anticuerpos completamente humanos contra 4-1bb humano | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| MXPA06003788A (es) | Anticuerpos completamente humanos contra 4-1bb humano (cd137). | |
| WO2004010947A3 (en) | Humanized antibodies against human 4-1bb | |
| GEP20074222B (en) | Antibodies to cd40 | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
| AR050642A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| CL2010000790A1 (es) | Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03). | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
| PE20121397A1 (es) | Anticuerpos especificos para cadherina-17 | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| UA89350C2 (uk) | Гуманізоване антитіло, що зв'язує людський cd20 | |
| NO20026063D0 (no) | Antistoffer mot human MCP-1 | |
| PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
| NZ596381A (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| NZ599196A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| PE20061166A1 (es) | Moleculas de anticuerpo que tienen especificidad para la il-17 humana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant; registration |